Current research and development of anti-pulmonary fibrosis drugs
10.3867/j.issn.1000-3002.2025.02.008
- VernacularTitle:抗肺纤维化药物研究进展
- Author:
Yuanying WANG
1
;
Qiao YE
1
Author Information
1. 首都医科大学附属北京朝阳医院职业病与中毒医学科,北京 100020;首都医科大学附属北京朝阳医院间质性肺疾病临床诊疗与研究中心,北京 100020
- Publication Type:Journal Article
- Keywords:
anti-plumonary fibrosis drugs;
pulmonary fibrosis;
idiopathic pulmonary fibrosis;
clinical trials
- From:
Chinese Journal of Pharmacology and Toxicology
2025;39(2):146-160
- CountryChina
- Language:Chinese
-
Abstract:
Along with more research into the mechanisms of pulmonary fibrosis,anti-pulmonary fibrosis drugs under development are becoming diversified.Over the past decade,multiple phase Ⅱ/Ⅲ clinical trials have been terminated due to insufficient efficacy,with seven single-target monoclonal anti-body drugs failing to meet expectations.In contrast,multi-target drugs such as nintedanib and pirfeni-done have been successfully marketed,demonstrating favorable clinical outcomes.However,drugs directly targeting transforming growth factor-β have raised safety concerns.Ongoing phase Ⅲ candi-dates,such as lysophosphatidic acid receptor 1 antagonists and phosphodiesterase 4B inhibitors,do not directly intervene in the transforming growth factor-β signaling pathway.Given the potential limita-tions of single-target drugs,future drug development is expected to prioritize multi-target and multi-cell strategies while exploring synergistic multi-drug therapies.This article reviews the current clinical trials for anti-pulmonary fibrosis drugs worldwide and the challenges they face in order to provide references for the research and development of new anti-pulmonary fibrosis drugs.
